SNAP-8
10 mg
Research Use Only
For research use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease. Must be 21 or older to purchase.
Measurement Key
mg = milligram; mcg = microgram; 1 mg = 1,000 mcg. mL = liquid volume. A U-100 syringe has 100 marked volume units per mL: one marking is 0.01 mL and ten are 0.10 mL. These markings are NOT peptide International Units (IU). A physical syringe may not have one-unit or half-unit graduations; do not imply it can measure a value more precisely than its scale permits. Concentration = total amount / measured FINAL volume. Quantity in a sample = concentration × sample volume. Required volume = a protocol-specified quantity / verified concentration. The calculator checks arithmetic only; it cannot select a clinical dose or establish suitability, stability or sterility.
Research Information
Contents
10 mg SNAP-8 / acetyl octapeptide-3; research material.
Clinical evidence and research limitations
Human cosmetic studies have included acetyl octapeptide-3 within multi-ingredient topical products. Any product-level improvements cannot be attributed to SNAP-8 alone. Injectable wrinkle reduction or a Botox-equivalent effect from this vial was not verified.
Dosing evidence
No verified injection dose or cycle. Topical research is described by the concentration in a finished formulation, not insulin-syringe units.
Reconstitution
This is a powder-vial calculation reference, not a validated preparation recipe. Confirm the exact formulation, compatible diluent, final volume, container capacity, mixing method and storage with the manufacturer. Do not interpret the example as a direction to add that volume of BAC water.
Measurement example
Topical formulation arithmetic only: 10 mg active peptide in 100 g of FINAL formulation = 0.01% by weight. This is not a recommended concentration or a formula; preservative, vehicle, stability and compatibility require validation. No injectable U-100 chart is appropriate.
Possible side effects
No reliable injected-product side-effect profile was established. Finished topical-product tolerability does not establish tolerance of this raw research material.
Storage
Follow the original lot-specific supplier instructions before and after preparation. Temperature, light protection, freezing limits and discard date: insufficient data to verify. The calculation volume does not establish stability or a use-by period.
Sources
Source access date: October 25, 2026. Secondary calculation references (peptidedosages.com) are community resources, not clinical trials. Their example volumes do not validate these products.
Responding to possible adverse effects: The side-effect summaries are incomplete and do not establish the safety of the inventory. Unknown risks must not be described as "no side effects." For anyone experiencing breathing difficulty, facial/throat swelling, fainting, severe persistent abdominal pain or other severe symptoms after an exposure, seek urgent medical care and provide the product/lot details.
Preparation and Handling Information
The original product instructions must establish substance identity, component ratio, excipients, compatible diluent, required amount, final volume, mixing method, container suitability, storage and discard interval. A 3 mL container does not automatically require 3 mL water. Any powder displacement and final-volume instructions must be accounted for. Do not transfer the storage rules for a branded finished medicine to a different research powder. No universal refrigerated shelf life, freezer shelf life or "28 days after mixing" period is established for this catalog. Lack of visible particles is not proof of sterility. Do not use a damaged, leaking, unexpectedly altered or undocumented preparation.